Burn Wound
Conditions
Brief summary
Burn patients meeting inclusion criteria will receive the esterified hyaluronic acid matrix as the matrix for their wound, in conjunction with the standard of care for managing these types of wounds. The study will be divided into two phases. Phase I will entail intervention with the wound matrix and will continue until one of the following occur, sufficient granulation has occurred and the patient can receive a STSG and proceed to Phase II, the patient's physician determines an STSG is no longer necessary or two applications with the wound matrix occur and no STSG is approved. Phase II will begin following the STSG procedure. In this phase, the wound will be monitored and proportion of STSG take will be evaluated but no application of the wound matrix device will take place. This phase will continue for 28 days or if the physician deems the patient no longer needs regular care to monitor the wound, whichever occurs earlier.
Interventions
DEVICEEsterified Hyaluronic Acid Matrix
A non-woven pad composed of esterified hyaluronic acid, covered with a semipermeable silicone layer to protect the wound and control water vapor loss
Sponsors
Medline Industries
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Has a wound originating from a thermal or electrical burn * Target burn area is less than 20% of TBSA * Target burn wound is greater than 0.5% of TBSA * Patient has undergone escharectomy procedure or will undergo escharectomy on the target burn and resulting wound will likely need a split thickness skin graft, but wound site is not immediately ready for grafting * For patients with diabetes, an A1C hemoglobin level between 11 percent (taken within 90 days)
Exclusion criteria
* Current active diagnosis of substance abuse, per the Investigator * Patient currently taking non-inhaled corticosteroids * Patient needs or is likely to need negative pressure wound therapy of the target wound after application of Hyalomatrix Wound Device * Patient is pregnant, planning to become pregnant during study period, or breastfeeding * Unstable medical condition as determined by the site investigator * Patients with known sensitivities to hyaluronan, hyaluronan derivatives, silicone, or any other ingredients of the Hyalomatrix Wound Device
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Days From Initial Application of Wound Matrix to Approval of Wound to Receive a Split Thickness Skin Graft | Baseline to 42 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Length of Stay in Inpatient Unit | Baseline to 42 days | — |
| Patient Pain Rating | Baseline to 42 days | — |
| Change in Wound Volume From the Time Prior to Application of the Wound Device to the Time Before the Application of STSG and After STSG | Baseline to 42 days | — |
| Proportion of Patients Who Develop an Infection of the Target Wound at Any Time Per Confirmation With Culture | Baseline to 70 days | — |
| Subject Discharge Destination | Baseline to 70 days | The facility that the subject is discharged to will be captured. |
| Proportion of Split Thickness Skin Graft Take for the Wound at 28 Days | 28 days | — |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Esterified Hyaluronic Acid Matrix Esterified Hyaluronic Acid Matrix: A non-woven pad composed of esterified hyaluronic acid, covered with a semipermeable silicone layer to protect the wound and control water vapor loss | 0 |
| Total | 0 |
Baseline characteristics
| Characteristic | — |
|---|---|
| Region of Enrollment United States | — participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 0 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
Primary
Number of Days From Initial Application of Wound Matrix to Approval of Wound to Receive a Split Thickness Skin Graft
Time frame: Baseline to 42 days
Population: Study was stopped due to business decision and data was not collected for analysis.
Secondary
Change in Wound Volume From the Time Prior to Application of the Wound Device to the Time Before the Application of STSG and After STSG
Time frame: Baseline to 42 days
Population: Study was stopped due to business decision and data was not collected for analysis.
Secondary
Length of Stay in Inpatient Unit
Time frame: Baseline to 42 days
Population: Study was stopped due to business decision and data was not collected for analysis.
Secondary
Patient Pain Rating
Time frame: Baseline to 42 days
Population: Study was stopped due to business decision and data was not collected for analysis.
Secondary
Proportion of Patients Who Develop an Infection of the Target Wound at Any Time Per Confirmation With Culture
Time frame: Baseline to 70 days
Population: Study was stopped due to business decision and data was not collected for analysis.
Secondary
Proportion of Split Thickness Skin Graft Take for the Wound at 28 Days
Time frame: 28 days
Population: Study was stopped due to business decision and data was not collected for analysis.
Secondary
Subject Discharge Destination
The facility that the subject is discharged to will be captured.
Time frame: Baseline to 70 days
Population: Study was stopped due to business decision and data was not collected for analysis.